Braster S.A.
Braster S.A. provides in-home breast cancer examination device worldwide. The company offers Braster System, a device that allows every woman to perform breast examination independently at home; and Braster Pro, a certified medical device that supports the process of breast examination in clinical conditions. It also provides automatic interpretation of results of thermographic breast examination… Read more
Braster S.A. (BRA) - Net Assets
Latest net assets as of March 2024: zł-5.04 Million PLN
Based on the latest financial reports, Braster S.A. (BRA) has net assets worth zł-5.04 Million PLN as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł18.64 Million) and total liabilities (zł23.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł-5.04 Million |
| % of Total Assets | -27.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.31% |
| 10-Year Change | -150.26% |
| Growth Volatility | 3743.41 |
Braster S.A. - Net Assets Trend (2011–2023)
This chart illustrates how Braster S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Braster S.A. (2011–2023)
The table below shows the annual net assets of Braster S.A. from 2011 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | zł-4.43 Million | -781.38% |
| 2022-12-31 | zł650.00K | -63.17% |
| 2021-12-31 | zł1.76 Million | -77.67% |
| 2020-12-31 | zł7.90 Million | -61.98% |
| 2019-12-31 | zł20.79 Million | -28.36% |
| 2018-12-31 | zł29.02 Million | -40.54% |
| 2017-12-31 | zł48.80 Million | +40.06% |
| 2016-12-31 | zł34.84 Million | -17.05% |
| 2015-12-31 | zł42.00 Million | +376.61% |
| 2014-12-31 | zł8.81 Million | +48.83% |
| 2013-12-31 | zł5.92 Million | -31.47% |
| 2012-12-31 | zł8.64 Million | +13456.63% |
| 2011-12-31 | zł63.73K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Braster S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12083822800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł2.94 Million | % |
| Other Components | zł114.74 Million | % |
| Total Equity | zł-4.43 Million | 100.00% |
Braster S.A. Competitors by Market Cap
The table below lists competitors of Braster S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
$2.89 Million |
|
Propanc Biopharma, Inc. Common Stock
PINK:PPCB
|
$2.89 Million |
|
Braille Energy Systems Inc
V:BES
|
$2.89 Million |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
$2.89 Million |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
$2.89 Million |
|
RALPH LAUREN-A
BE:PRL
|
$2.89 Million |
|
Rumbu Holdings Ltd.
V:RMB
|
$2.89 Million |
|
TERABYTE PLUS PUBLIC COMPANY LIMITED
BK:TERA
|
$2.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Braster S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 650,000 to -4,429,000, a change of -5,079,000 (-781.4%).
- Net loss of 4,748,000 reduced equity.
- Other comprehensive income decreased equity by 2,516,000.
- Other factors increased equity by 2,185,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-4.75 Million | -107.2% |
| Other Comprehensive Income | zł-2.52 Million | -56.81% |
| Other Changes | zł2.19 Million | +49.33% |
| Total Change | zł- | -781.38% |
Book Value vs Market Value Analysis
This analysis compares Braster S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | zł0.03 | zł0.58 | x |
| 2012-12-31 | zł3.49 | zł0.58 | x |
| 2013-12-31 | zł2.37 | zł0.58 | x |
| 2014-12-31 | zł2.10 | zł0.58 | x |
| 2015-12-31 | zł7.48 | zł0.58 | x |
| 2016-12-31 | zł5.65 | zł0.58 | x |
| 2017-12-31 | zł5.32 | zł0.58 | x |
| 2018-12-31 | zł3.16 | zł0.58 | x |
| 2019-12-31 | zł1.09 | zł0.58 | x |
| 2020-12-31 | zł0.32 | zł0.58 | x |
| 2021-12-31 | zł0.07 | zł0.58 | x |
| 2022-12-31 | zł0.02 | zł0.58 | x |
| 2023-12-31 | zł-0.15 | zł0.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Braster S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1488.40%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-165.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -479.08% | 0.00% | 0.00x | 11.93x | zł-311.68K |
| 2012 | -18.71% | 0.00% | 0.00x | 1.04x | zł-2.48 Million |
| 2013 | -50.98% | 0.00% | 0.00x | 1.07x | zł-3.61 Million |
| 2014 | -38.62% | 0.00% | 0.00x | 1.55x | zł-4.28 Million |
| 2015 | -9.56% | 0.00% | 0.00x | 1.13x | zł-8.21 Million |
| 2016 | -41.30% | -3369.56% | 0.01x | 1.86x | zł-17.87 Million |
| 2017 | -51.01% | -6270.03% | 0.01x | 1.51x | zł-29.77 Million |
| 2018 | -68.18% | -2284.30% | 0.02x | 1.88x | zł-22.68 Million |
| 2019 | -74.74% | -2665.01% | 0.01x | 2.35x | zł-17.62 Million |
| 2020 | -202.32% | -8371.20% | 0.01x | 4.54x | zł-16.78 Million |
| 2021 | -515.86% | -2088.30% | 0.02x | 13.45x | zł-9.28 Million |
| 2022 | -601.08% | -174.42% | 0.09x | 37.39x | zł-3.97 Million |
| 2023 | 0.00% | -1488.40% | 0.02x | 0.00x | zł-4.31 Million |
Industry Comparison
This section compares Braster S.A.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $36,123,358
- Average return on equity (ROE) among peers: -77.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Braster S.A. (BRA) | zł-5.04 Million | -479.08% | N/A | $2.89 Million |
| Adiuvo Investment SA (ADV) | $7.30 Million | -237.44% | 6.75x | $685.90K |
| Genomtec S.A. (GMT) | $7.57 Million | -144.47% | 0.24x | $14.99 Million |
| Medinice S.A (ICE) | $8.23 Million | -27.31% | 0.42x | $49.49 Million |
| Medicalg (MDG) | $99.19 Million | 14.04% | 0.03x | $34.29 Million |
| Synektik S.A. (SNT) | $58.33 Million | 6.18% | 0.83x | $268.09 Million |